Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Dystonia - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dystonia - Pipeline Review, H2 2016, provides an overview of the Dystonia (Central Nervous System) pipeline landscape. Dystonia is a movement disorder that causes the muscles to contract and spasm involuntarily. The movements may be painful, and some individuals with dystonia may have a tremor or other neurologic features. Symptoms include involuntary muscle contractions that cause repetitive movements or distorted postures, stress, fatigue or anxiety and speech difficulties. Treatment includes anticholinergic and benzodiazepines. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dystonia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dystonia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Dystonia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dystonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively for Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively for Dystonia. Dystonia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Dystonia (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Dystonia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Dystonia (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Dystonia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Dystonia (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Dystonia (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Dystonia (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Dystonia Overview 6 Therapeutics Development 7 Pipeline Products for Dystonia - Overview 7 Pipeline Products for Dystonia - Comparative Analysis 8 Dystonia - Therapeutics under Development by Companies 9 Dystonia - Therapeutics under Investigation by Universities/Institutes 10 Dystonia - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Dystonia - Products under Development by Companies 13 Dystonia - Products under Investigation by Universities/Institutes 14 Dystonia - Companies Involved in Therapeutics Development 15 Addex Therapeutics Ltd 15 Advicenne SA 16 EpiVax, Inc. 17 Ipsen S.A. 18 Revance Therapeutics, Inc. 19 Dystonia - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 abobotulinumtoxin A - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 dipraglurant ER - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 onabotulinumtoxinA - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 RT-002 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 tetrabenazine - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Dystonia - Dormant Projects 39 Dystonia - Product Development Milestones 40 Featured News & Press Releases 40 Mar 05, 2016: Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology 40 Oct 29, 2015: Revance Reports Positive 6-Month Duration in BELMONT Study 41 Sep 29, 2015: Revance Therapeutics Initiates Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A for Injection to Treat Cervical Dystonia 43 Feb 26, 2007: Epivax Funded To Advance Research On A New, Improved "Botox" 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Number of Products under Development for Dystonia, H2 2016 7 Number of Products under Development for Dystonia - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Dystonia - Pipeline by Addex Therapeutics Ltd, H2 2016 15 Dystonia - Pipeline by Advicenne SA, H2 2016 16 Dystonia - Pipeline by EpiVax, Inc., H2 2016 17 Dystonia - Pipeline by Ipsen S.A., H2 2016 18 Dystonia - Pipeline by Revance Therapeutics, Inc., H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Number of Products by Stage and Target, H2 2016 22 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 28 Dystonia - Dormant Projects, H2 2016 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.